Details of the Drug

General Information of Drug (ID: DMXV116)

Drug Name
PF-05180999
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Phase 1 [1]
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C19H17F3N8
Canonical SMILES
CC1=NC(=C2N1N=CN=C2N3CCC3)C4=C(N(N=C4)C)C5=NC=C(C=C5)C(F)(F)F
InChI
InChI=1S/C19H17F3N8/c1-11-27-15(17-18(29-6-3-7-29)24-10-26-30(11)17)13-9-25-28(2)16(13)14-5-4-12(8-23-14)19(20,21)22/h4-5,8-10H,3,6-7H2,1-2H3
InChIKey
CLGCHUKGBICQTE-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
60143346
ChEBI ID
CHEMBL3092562
CAS Number
1394033-54-5
UNII
5L84K4IEN9
DrugBank ID
DB14885
TTD ID
D07GHV
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

References

1 ClinicalTrials.gov (NCT01530529) A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999. U.S. National Institutes of Health.